The Safety, Feasibility and Efficacy of NouvNeu001 for Parkinson's Disease

Inclusion Criteria: * Age 50-75 years old, male or female * Able to understand the rationale of the clinical trial and sign informed consent form (ICF) * Diagnosis of Parkinson's Disease in accordance with the MDS clinical diagnostic criteria for Parkinson's disease (2015)，Parkinson's disease history of ≥ 4 years * Medically suitable for neurosurgery under anesthesia and able to participate in Computerized Tomography (CT) and Magnetic Resonance Imaging (MRI) and Positron Emission Tomography (PET) scan * Hoehn-Yahr staging for "off" episodes is 2.5 to 4 * The MDS-UPDRS Part III (MDS-UPDRS-III) score in the "off" state \> 35, and positive for the Acute Levodopa Challenge Test (ALCT) * Currently undergoing treatment with levodopa drugs, but with poor control of motor symptoms or reduced efficacy * Receive a stable dose of anti-Parkinson's disease drugs for at least 4 weeks before administration * Acceptable laboratory test results during screening and prior to transplantation * The patients agreed to postpone any other elective neurosurgery, including deep brain stimulation (DBS), until the completion of the 24-month follow-up * The patients agreed not to participate in any other interventional clinical studies within 24 months after administration * The patients agreed not to receive any vaccines within 30 days after administration Exclusion Criteria: * Atypical or secondary Parkinson's syndrome to be caused by drugs, metabolic disorders or other reasons * The patients who h…